The Crary laboratory is located at the Icahn School of Medicine at Mount Sinai, on the upper east side of the borough of Manhattan in New York City. The ISMMS received $318.4 million in National Institutes of Health (NIH) funding awarded in 2017 making it 13th among U.S. medical schools and is 1st in research dollars per principal investigator among U.S. medical schools by the Association of American Medical Colleges (AAMC). The ISMMS has 36 multidisciplinary research, educational, and clinical institutes and 33 academic departments, with an annual budget of $2.7 billion. There are more than 6,369 full-time, part-time, and voluntary faculty. The ISMMS was named 4th among “World’s Most Innovative Companies in Data Science” by Fast Company magazine in 2016.
Dr. Crary, a Brooklyn native, went to high school at Saint Ann's School. Subsequently, he went to college at Brown University and majored in neuroscience. This is where he fell in love with brain research, conducting a project looking at NMDA mediated pain processing in the trigeminal system with Dr. David Bereiter. Later, he received is MD-PhD from SUNY Downstate Medical Center, working under Drs. Todd Sacktor (Neurology/Pharmacology) and Suzanne Mirra (Pathology). It is at this time that he developed a strong interest in the neuropathology of Alzheimer's disease, particularly neurofibrillary type degeneration. His thesis research highlighted a unique pattern of neurofibrillary degeneration in the limbic system that is associated with an atypical protein kinase C isoform. Later, Dr. Crary did his residency and fellowship training in neuropathology at Columbia University Medical Center and stayed on as an assistant professor under the mentorship of Dr. Michael Shelanski. Here, he conducted seminal work that led to the description of primary age-related tauopathy (PART). In 2014, Dr. Crary established a new neuropathology laboratory at Mount Sinai to continue this work and expand it to other neurodegenerative tauopathies, including chronic traumatic encephalopathy and progressive supranuclear palsy. Dr. Crary has numerous federal and foundation grants to study these diseases. Dr. Crary is a member of the editorial board of Acta Neuropathological and is a frequent contributor to the Tau Consortium.